Mason MD - Search Results

1

Analysis of antigen presenting cell derived exosomes, based on immuno-magnetic isolation and flow cytometry.

Clayton A, Court J, Navabi H, Adams M, Mason MD, Hobot JA, Newman GR, Jasani B. Clayton A, et al. Among authors: mason md. J Immunol Methods. 2001 Jan 1;247(1-2):163-74. doi: 10.1016/s0022-1759(00)00321-5. J Immunol Methods. 2001. PMID: 11150547

2

Increased exosome production from tumour cell cultures using the Integra CELLine Culture System.

Mitchell JP, Court J, Mason MD, Tabi Z, Clayton A. Mitchell JP, et al. Among authors: mason md. J Immunol Methods. 2008 Jun 1;335(1-2):98-105. doi: 10.1016/j.jim.2008.03.001. Epub 2008 Apr 3. J Immunol Methods. 2008. PMID: 18423480

3

Antigen-presenting cell exosomes are protected from complement-mediated lysis by expression of CD55 and CD59.

Clayton A, Harris CL, Court J, Mason MD, Morgan BP. Clayton A, et al. Among authors: mason md. Eur J Immunol. 2003 Feb;33(2):522-31. doi: 10.1002/immu.200310028. Eur J Immunol. 2003. PMID: 12645951 Free article.

4

Induction of heat shock proteins in B-cell exosomes.

Clayton A, Turkes A, Navabi H, Mason MD, Tabi Z. Clayton A, et al. Among authors: mason md. J Cell Sci. 2005 Aug 15;118(Pt 16):3631-8. doi: 10.1242/jcs.02494. Epub 2005 Jul 26. J Cell Sci. 2005. PMID: 16046478

5

Recovery of CD8+ T-cell function during systemic chemotherapy in advanced ovarian cancer.

Coleman S, Clayton A, Mason MD, Jasani B, Adams M, Tabi Z. Coleman S, et al. Among authors: mason md. Cancer Res. 2005 Aug 1;65(15):7000-6. doi: 10.1158/0008-5472.CAN-04-3792. Cancer Res. 2005. PMID: 16061686

6

Human tumor-derived exosomes selectively impair lymphocyte responses to interleukin-2.

Clayton A, Mitchell JP, Court J, Mason MD, Tabi Z. Clayton A, et al. Among authors: mason md. Cancer Res. 2007 Aug 1;67(15):7458-66. doi: 10.1158/0008-5472.CAN-06-3456. Cancer Res. 2007. PMID: 17671216

7

Human tumor-derived exosomes down-modulate NKG2D expression.

Clayton A, Mitchell JP, Court J, Linnane S, Mason MD, Tabi Z. Clayton A, et al. Among authors: mason md. J Immunol. 2008 Jun 1;180(11):7249-58. doi: 10.4049/jimmunol.180.11.7249. J Immunol. 2008. PMID: 18490724

8

Generation of in vitro autologous human cytotoxic T-cell response to E7 and HER-2/neu oncogene products using ex-vivo peptide loaded dendritic cells.

Navabi H, Jasani B, Adams M, Evans AS, Mason M, Crosby T, Borysiewicz L. Navabi H, et al. Adv Exp Med Biol. 1997;417:583-9. doi: 10.1007/978-1-4757-9966-8_94. Adv Exp Med Biol. 1997. PMID: 9286422 No abstract available.

9

Dendritic cell (DC) based therapy for cervical cancer: use of DC pulsed with tumour lysate and matured with a novel synthetic clinically non-toxic double stranded RNA analogue poly [I]:poly [C(12)U] (Ampligen R).

Adams M, Navabi H, Jasani B, Man S, Fiander A, Evans AS, Donninger C, Mason M. Adams M, et al. Vaccine. 2003 Jan 30;21(7-8):787-90. doi: 10.1016/s0264-410x(02)00599-6. Vaccine. 2003. PMID: 12531360 Review.

10

A clinical grade poly I:C-analogue (Ampligen) promotes optimal DC maturation and Th1-type T cell responses of healthy donors and cancer patients in vitro.

Navabi H, Jasani B, Reece A, Clayton A, Tabi Z, Donninger C, Mason M, Adams M. Navabi H, et al. Vaccine. 2009 Jan 1;27(1):107-15. doi: 10.1016/j.vaccine.2008.10.024. Epub 2008 Oct 31. Vaccine. 2009. PMID: 18977262

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

289 results

Search Page

Filters